Big Pharma's Role-Reversal in Licensing
1998 saw a significant leveling off in Big Pharma's licensing spending, as many players were too preoccupied with mergers and restructuring to pay much attention to in-licensing opportunities. Alliance watch tracks total alliance dollar volume by development phase from 1995-1998.
You may also be interested in...
The US agency has released a document explaining what COVID-19 testing supplies may be substituted.
Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.
AstraZeneca and Accent Therapeutics will jointly discover, develop and commercialize novel therapeutics targeting RNA-modifying proteins for the treatment of cancer.